Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™…
<!-- Name:DistributionId Value:8799097 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
ADPD
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of…
<!-- Name:DistributionId Value:8796446 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
Boca Raton, Florida, March 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments…
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of…
BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore…
Nitrase Therapeutics Announces Major Discovery In Parkinson’s Disease Presented At…
-Company Identifies Potential New Biomarker And Diagnostic For Parkinson’s Disease- SAN FRANCISCO, March 18, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc. (formerly Nitrome…
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD…
Oral presentation on preclinical data demonstrates Prothena’s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer’s, generated anti-Aβ and anti-tau antibodies to…
Biogen to Present New Research at the International Conference on Alzheimer’s and…
CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM®…
AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for…
Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM) AC Immune’s Chief Medical Officer to participate in expert forum on translational…